ArticleCardiovascular diabetology2026
Impaired lymphangiogenesis in pericoronary adipose tissue correlates with diabetes-aggravated coronary atherosclerosis.
Article in Cardiovascular diabetology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
backgroundEpicardial adipose tissue (EpAT), particularly pericoronary adipose tissue (PCAT), plays a crucial role in diabetes mellitus (DM)-aggravated coronary artery disease (CAD). Emerging evidence suggests that dysfunction of the arterial lymphatic network contributes to atherosclerosis progression. Our study aimed to investigate whether lymphatic vessel impairment in PCAT (a type of EpAT) is involved in DM-related CAD and to explore its underlying molecular mechanisms.
methodsWe prospectively enrolled patients undergoing heart valve surgery (control [CTRL] group) and coronary artery bypass grafting surgery (CAD group) between February 2024 and March 2025. EpAT volume (EpATv) and SYNTAX scores were assessed, and human PCAT samples were performed with pathological staining. Single-nucleus RNA sequencing (snRNA-seq) was employed to characterize intercellular communication between epicardial adipocytes and lymphatic endothelial cells (LECs). In vitro diabetic models of human adipocytes and LECs were established using palmitic acid (PA) and high concentration glucose (HG) to verify intercellular signaling.
resultsOf a total of 160 patients enrolled (113 males), 48 were controls and 112 were CAD patients (44 with DM). CAD patients, particularly those with DM, showed increased EpATv, adipocyte size, macrophage infiltration, and reduced lymphatic vessel density. Lymphatic vessel density was inversely correlated with both adipocyte size and CAD severity. CAD patients with DM also had worse prognosis and higher readmission rates. snRNA-seq analysis revealed significantly attenuated IGF1-IGF1R signaling between epicardial adipocytes and LECs in the PCAT of CAD patients with DM. Recombinant IGF1 effectively enhanced LEC proliferation, migration, and tube formation under diabetic conditions, whereas the IGF1R antagonist impeded these protective effects.
conclusionsOur findings demonstrate that attenuated IGF1-IGF1R signaling between epicardial adipocytes and LECs may contribute to lymphatic impairment in PCAT, which is associated with CAD progression in DM. Our work may represent a novel potential therapeutic target for CAD patients with DM. RESEARCH INSIGHTS: What is currently known about this topic? Lymphatic vessels play a crucial role in mediating the progression of atherosclerosis. Epicardial adipose tissue (EpAT) acts as critical anatomical and functional link coupling diabetes mellitus (DM) and coronary artery disease (CAD). Adipocytes are involved in the regulation of lymphatic endothelial cell proliferation and lymphangiogenesis. What is the key research question? Whether impaired lymphatic vessels in pericoronary adipose tissue (PCAT, a type of EpAT) were involved in the pathological development of DM-related CAD. What is new? DM-aggravated CAD is associated with reduced lymphatic vessel density within PCAT. It identifies a novel intercellular signaling interaction between epicardial adipocytes and lymphatic endothelial cells in modulating lymphangiogenesis. How might this study influence clinical practice? Enhancing lymphangiogenesis through modulation of IGF1-IGF1R signaling pathway may offer new strategies for improving cardiovascular outcomes. Additionally, lymphatic vessel density in PCAT may serve as a biomarker for CAD severity and progression. This work highlights a novel potential therapeutic target for CAD patients with DM.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.